NASDAQ · Drug Manufacturers - Specialty & Generic

Alvotech (ALVO) Stock

$5.78 +1.94% NASDAQ: ALVO Healthcare

Valuation

MetricValue
Price$5.78
Market Cap$1.95B
P/E Ratio-10.01
P/B Ratio-10.90
P/S Ratio4.02
EPS (TTM)$0.10
52-Week High$9.05
52-Week Low$2.94
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE76.83%
ROA-11.31%
ROCE3.77%
Gross Margin13.31%
Operating Margin13.31%
Net Margin-36.51%
Debt/Equity-7.58
Current Ratio1.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$37.0M$83.0M$91.0M$490.0M$586.0M
Operating Profit$-235.0M$-346.0M$-355.0M$70.0M$78.0M
Net Profit$-102.0M$-514.0M$-552.0M$-232.0M$28.0M
EPS$-3.25$-2.60$-2.43$-0.87$0.10
Op Margin-640.3%-417.3%-388.1%14.2%13.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$598.0M$828.0M$950.0M$1.2B$1.5B
Total Liabilities$734.0M$1.4B$1.9B$1.6B$1.8B
Cash$18.0M$66.0M$11.0M$51.0M$172.0M
Borrowings$523.0M$805.0M$1.1B$1.2B$1.4B

Latest News

Alvotech Faces 'Soft' Q2 but Well Positioned to Benefit From Upcoming Biosimilar Opportunity, UBS Says MT Newswires · Jul 6, 2026 Transactions of Managers and Closely Associated Persons GlobeNewswire · Jul 3, 2026 Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering Simply Wall St. · Jul 2, 2026 Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO) Simply Wall St. · Jul 2, 2026 Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Fed Chair Warsh's International Debut MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-228.0M$-312.0M$-312.0M$-237.0M$-50.0M
Investing Cash Flow$-81.0M$-113.0M$-93.0M$-76.0M$-169.0M
Financing Cash Flow$0$157.0M$-7.0M$-5.0M$-10.0M
Net Cash Flow$-14.0M$49.0M$-55.0M$40.0M$121.0M
Free Cash Flow$-269.0M$-361.0M$-359.0M$-294.0M$-115.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.11
EV / EBITDA-2307.10
FCF Yield-15.17%
Quick Ratio0.96
Interest Coverage0.30
Return 1Y-65.28%
Return 3Y-68.42%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMGNAmgen Inc. $414.87 +1.82% 25.56 $223.91B 2.43%
AMPHAmphastar Pharmaceuticals, Inc. $26.62 +3.14% 14.50 $1.17B 0.00%
AMRXAmneal Pharmaceuticals, Inc. $19.91 +1.32% 36.74 $6.36B 0.00%
BIIBBiogen Inc. $225.71 +3.33% 40.07 $33.35B 0.00%
COLLCollegium Pharmaceutical, Inc. $22.09 -0.09% 14.47 $716.46M 0.00%

About Alvotech

Alvotech is led by CEO Lisa Graver, employs 1,012 people, headquartered in IS, publicly traded since 2022.

Alvotech (ALVO) stock trades at $5.78 with a market capitalization of $1.95B. The stock is valued at a price-to-earnings (P/E) ratio of -10.01, price-to-book of -10.90, price-to-sales of 4.02. Over the past 52 weeks the stock has ranged between $2.94 and $9.05, and currently trades 36.1% below its 52-week high.

On profitability, Alvotech generates a return on equity (ROE) of 76.83% — well above the market average, a sign of a high-quality business, return on capital employed of 3.77%, an operating margin of 13.31%, a net profit margin of -36.51%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides